Risks and benefits of human germline genome editing: An ethical analysis
With the arrival of new methods of genome editing, especially CRISPR/Cas 9, new perspectives on germline interventions have arisen. Supporters of germ line genome editing (GGE) claim that the procedure could be used as a means of disease prevention. As a possible life-saving therapy, it provides benefits that outweigh its risks. Opponents of GGE claim that the medical and societal risks, especially the use of GGE for genetic enhancement, are too high. In our paper, we analyze the risks and benefits of GGE. We show that the medical risk on an individual level might be reduced by further research in the near future so that they may be outweighed by the benefits. We also show that the societal risks of the procedure, i.e. genetic enhancement, are manageable by establishing a regulative framework before the GGE is implemented. Since the effects of modifying genes for the genepool of a given population are extremely difficult to model, the medical risks on the population level might be too high.
KeywordsBioethics CRISPR/Cas9 Disease prevention Genome editing Germ cells Germline therapy
- Baltimore, D., P. Berg, M. Botchan, D. Carroll, R.A. Charo, G. Church, J.E. Corn, G.Q. Daley, J.A. Doudna, M. Fenner, H.T. Greely, M. Jinek, G.S. Martin, E. Penhoet, J. Puck, S.H. Stemberg, J.S. Weissman, and K.R. Yamamoto. 2015. A prudent path forward for genomic engineering and germline gene modification. Science 348: 36–38. https://doi.org/10.1126/science.aab1028.CrossRefGoogle Scholar
- Callaway, E. 2016. UK scientists gain licence to edit genes in human embryos. Nature 530. https://doi.org/10.1038/nature.2016.19270.
- Hildt, E. 2016. Human germline interventions–think first. Frontiers in Genetics 7. https://doi.org/10.3389/fgene.2016.00081.
- Kang, X., W. He, Y. Huang, Q. Yu, Y. Chen, X. Gao, X. Sun, and Y. Fan. 2016. Introducing precise genetic modifications into human 3PN-embryos by CRISPR/Cas-mediated genome editing. Journal of Assisted Reproduction and Genetics 33: 581–588. https://doi.org/10.1007/s10815-016-0710-8.CrossRefGoogle Scholar
- Liang, P., Y. Xu, X. Zhang, C. Ding, R. Huang, Z. Zhang, J. Lu, X. Xie, Y. Chen, Y. Li, Y. Sun, Y. Bai, S. Zhou, W. Ma, C. Zhou, and J. Huang. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell 6: 363–372. https://doi.org/10.1007/s13238-015-0153-5.CrossRefGoogle Scholar
- Ma, Hong, N. Marti-Gutierrez, J. Wu S-W Park, Y. Lee, K. Suzuki, A. Koski, D. Ji, T. Hayama, R. Ahmed, H. Darby, C. Van Dyken, Y. Li, E. Kang, A.-R. Park, D. Kim, S.-T. Kim, J. Gong, Y. Gu, X. Xu, D. Battaglia, S.A. Krieg, D.M. Lee, D.H. Wu, D.P. Wolf, S.B. Heitner, J.C. Izpisua Belmonte, P. Amato, J.-S. Kim, S. Kaul, and S. Mitalipov. 2017. Correction of a pathogenic gene mutation in human embryos. Nature 548: 413–419. https://doi.org/10.1038/nature23305.CrossRefGoogle Scholar
- Ormond, K.E., D.P. Mortlock, D.T. Scholes, Y. Bombard, L.C. Brody, W.A. Faucett, N.A. Garrison, L. Hercher, R. Isassi, A. Middleton, K. Musunuru, D. Shriner, A. Virani, and C.E. Young. 2017. Human Germline Genome Editing. American Journal of Human Genetics 101: 167–176. https://doi.org/10.1016/j.ajhg.2017.06.012. CrossRefGoogle Scholar
- Powell, R. 2015. In genes we trust: Germline engineering, eugenics, and the future of the human genome. Journal of Medicine and Philosophy 40:669–695. https://doi.org/10.1093/jmp/jhv025.
- Rubeis, G., and F. Steger. 2016. Genome Editing in der Pränatalmedizin. Eine medizinethische Analyse. In Jahrbuch für Recht und Ethik - Annual Review of Law and Ethics, ed. Sharon B. Byrd, Joachim Hruschka, and Jan C. Joerden, vol. 24, 143–159. Berlin: Duncker & Humblot.Google Scholar
- The National Academies of Sciences, Engineering, and Medicine. 2017. Human genome editing: science, ethics, and governance. https://doi.org/10.17226/24623.